Edwards Lifesciences Corporation (EW)
USD 72.81
(-1.77%)
USD 72.81
(-1.77%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 694.9 Million USD | 0.52% |
| 2022 | 691.3 Million USD | 0.14% |
| 2021 | 690.3 Million USD | -0.66% |
| 2020 | 694.9 Million USD | 2.37% |
| 2019 | 678.8 Million USD | 14.31% |
| 2018 | 593.8 Million USD | -42.71% |
| 2017 | 1.03 Billion USD | 26.04% |
| 2016 | 822.3 Million USD | 37.07% |
| 2015 | 599.9 Million USD | 0.3% |
| 2014 | 598.1 Million USD | 0.84% |
| 2013 | 593.1 Million USD | 213.31% |
| 2012 | 189.3 Million USD | 25.86% |
| 2011 | 150.4 Million USD | 259.81% |
| 2010 | 41.8 Million USD | -53.71% |
| 2009 | 90.3 Million USD | -48.55% |
| 2008 | 175.5 Million USD | -17.1% |
| 2007 | 211.7 Million USD | -10.26% |
| 2006 | 235.9 Million USD | -25.37% |
| 2005 | 316.1 Million USD | 18.35% |
| 2004 | 267.1 Million USD | 4.42% |
| 2003 | 255.8 Million USD | 4.2% |
| 2002 | 245.5 Million USD | -21.06% |
| 2001 | 311 Million USD | -27.34% |
| 2000 | 428 Million USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 693 Million USD | -0.89% |
| 2024 Q1 | 699.2 Million USD | 0.62% |
| 2023 Q4 | 694.9 Million USD | 0.55% |
| 2023 Q1 | 687.8 Million USD | -0.51% |
| 2023 Q2 | 684.5 Million USD | -0.48% |
| 2023 Q3 | 691.1 Million USD | 0.96% |
| 2023 FY | 694.9 Million USD | 0.52% |
| 2022 Q4 | 691.3 Million USD | 0.66% |
| 2022 Q3 | 686.8 Million USD | 0.59% |
| 2022 Q1 | 688.2 Million USD | -0.3% |
| 2022 Q2 | 682.8 Million USD | -0.78% |
| 2022 FY | 691.3 Million USD | 0.14% |
| 2021 Q2 | 684.2 Million USD | -0.67% |
| 2021 Q4 | 690.3 Million USD | 0.91% |
| 2021 FY | 690.3 Million USD | -0.66% |
| 2021 Q1 | 688.8 Million USD | -0.88% |
| 2021 Q3 | 684.1 Million USD | -0.01% |
| 2020 Q1 | 675.2 Million USD | -0.53% |
| 2020 Q2 | 684.5 Million USD | 1.38% |
| 2020 FY | 694.9 Million USD | 2.37% |
| 2020 Q4 | 694.9 Million USD | 0.7% |
| 2020 Q3 | 690.1 Million USD | 0.82% |
| 2019 Q1 | 666.2 Million USD | 12.19% |
| 2019 Q3 | 670.7 Million USD | 0.36% |
| 2019 FY | 678.8 Million USD | 14.31% |
| 2019 Q4 | 678.8 Million USD | 1.21% |
| 2019 Q2 | 668.3 Million USD | 0.32% |
| 2018 Q1 | 1.05 Billion USD | 1.76% |
| 2018 FY | 593.8 Million USD | -42.71% |
| 2018 Q4 | 593.8 Million USD | -50.25% |
| 2018 Q2 | 1.19 Billion USD | 13.13% |
| 2018 Q3 | 1.19 Billion USD | 0.03% |
| 2017 Q2 | 1.01 Billion USD | 19.92% |
| 2017 FY | 1.03 Billion USD | 26.04% |
| 2017 Q4 | 1.03 Billion USD | 0.23% |
| 2017 Q3 | 1.03 Billion USD | 1.69% |
| 2017 Q1 | 847.9 Million USD | 3.11% |
| 2016 Q3 | 600.6 Million USD | -0.32% |
| 2016 Q1 | 602.2 Million USD | 0.38% |
| 2016 Q4 | 822.3 Million USD | 36.91% |
| 2016 FY | 822.3 Million USD | 37.07% |
| 2016 Q2 | 602.5 Million USD | 0.05% |
| 2015 Q3 | 604.9 Million USD | 0.77% |
| 2015 Q1 | 602.7 Million USD | 0.77% |
| 2015 FY | 599.9 Million USD | 0.3% |
| 2015 Q2 | 600.3 Million USD | -0.4% |
| 2015 Q4 | 599.9 Million USD | -0.83% |
| 2014 Q3 | 596.4 Million USD | -0.27% |
| 2014 Q1 | 725.4 Million USD | 22.31% |
| 2014 Q2 | 598 Million USD | -17.56% |
| 2014 FY | 598.1 Million USD | 0.84% |
| 2014 Q4 | 598.1 Million USD | 0.29% |
| 2013 Q2 | 227.3 Million USD | 17.96% |
| 2013 Q3 | 532.1 Million USD | 134.1% |
| 2013 Q4 | 593.1 Million USD | 11.46% |
| 2013 FY | 593.1 Million USD | 213.31% |
| 2013 Q1 | 192.7 Million USD | 1.8% |
| 2012 Q4 | 189.3 Million USD | 7.92% |
| 2012 FY | 189.3 Million USD | 25.86% |
| 2012 Q3 | 175.4 Million USD | -5.24% |
| 2012 Q2 | 185.1 Million USD | 3.18% |
| 2012 Q1 | 179.4 Million USD | 19.28% |
| 2011 FY | 150.4 Million USD | 259.81% |
| 2011 Q4 | 150.4 Million USD | -14.06% |
| 2011 Q3 | 175 Million USD | 0.11% |
| 2011 Q2 | 174.8 Million USD | 16.92% |
| 2011 Q1 | 149.5 Million USD | 257.66% |
| 2010 FY | 41.8 Million USD | -53.71% |
| 2010 Q2 | 177.5 Million USD | 37.28% |
| 2010 Q4 | 41.8 Million USD | -58.45% |
| 2010 Q3 | 100.6 Million USD | -43.32% |
| 2010 Q1 | 129.3 Million USD | 43.19% |
| 2009 Q4 | 90.3 Million USD | -11.73% |
| 2009 Q3 | 102.3 Million USD | -10.18% |
| 2009 Q1 | 123 Million USD | -29.91% |
| 2009 Q2 | 113.9 Million USD | -7.4% |
| 2009 FY | 90.3 Million USD | -48.55% |
| 2008 FY | 175.5 Million USD | -17.1% |
| 2008 Q1 | 212.9 Million USD | 0.57% |
| 2008 Q2 | 141.7 Million USD | -33.44% |
| 2008 Q3 | 202.8 Million USD | 43.12% |
| 2008 Q4 | 175.5 Million USD | -13.46% |
| 2007 Q4 | 211.7 Million USD | 0.24% |
| 2007 Q1 | 224.5 Million USD | -4.83% |
| 2007 Q2 | 207.6 Million USD | -7.53% |
| 2007 Q3 | 211.2 Million USD | 1.73% |
| 2007 FY | 211.7 Million USD | -10.26% |
| 2006 Q3 | 253 Million USD | -9.51% |
| 2006 FY | 235.9 Million USD | -25.37% |
| 2006 Q4 | 235.9 Million USD | -6.76% |
| 2006 Q2 | 279.6 Million USD | -3.25% |
| 2006 Q1 | 289 Million USD | -8.57% |
| 2005 Q2 | 269.6 Million USD | -2.25% |
| 2005 Q4 | 316.1 Million USD | 25.69% |
| 2005 Q3 | 251.5 Million USD | -6.71% |
| 2005 FY | 316.1 Million USD | 18.35% |
| 2005 Q1 | 275.8 Million USD | 3.26% |
| 2004 Q1 | 334.5 Million USD | 30.77% |
| 2004 Q2 | 312.8 Million USD | -6.49% |
| 2004 Q3 | 269.2 Million USD | -13.94% |
| 2004 Q4 | 267.1 Million USD | -0.78% |
| 2004 FY | 267.1 Million USD | 4.42% |
| 2003 Q4 | 255.8 Million USD | -12.73% |
| 2003 Q1 | 276.9 Million USD | 12.79% |
| 2003 Q2 | 307.3 Million USD | 10.98% |
| 2003 FY | 255.8 Million USD | 4.2% |
| 2003 Q3 | 293.1 Million USD | -4.62% |
| 2002 Q3 | 279.9 Million USD | -5.92% |
| 2002 Q4 | 245.5 Million USD | -12.29% |
| 2002 Q2 | 297.5 Million USD | 1.78% |
| 2002 Q1 | 292.3 Million USD | -6.01% |
| 2002 FY | 245.5 Million USD | -21.06% |
| 2001 FY | 311 Million USD | -27.34% |
| 2001 Q1 | 414.4 Million USD | -3.18% |
| 2001 Q4 | 311 Million USD | -8.34% |
| 2001 Q3 | 339.3 Million USD | -12.6% |
| 2001 Q2 | 388.2 Million USD | -6.32% |
| 2000 FY | 428 Million USD | 0.0% |
| 2000 Q4 | 428 Million USD | -14.19% |
| 2000 Q3 | 498.8 Million USD | -6.06% |
| 2000 Q2 | 531 Million USD | 0.38% |
| 2000 Q1 | 529 Million USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Abbott Laboratories | 15.87 Billion USD | 95.622% |
| Allurion Technologies Inc. | 41.85 Million USD | -1560.176% |
| Artivion, Inc. | 359.34 Million USD | -93.382% |
| Avanos Medical, Inc. | 209.1 Million USD | -232.329% |
| Butterfly Network, Inc. | 25.02 Million USD | -2676.601% |
| Butterfly Network, Inc. | 25.02 Million USD | -2676.601% |
| Bio-Rad Laboratories, Inc. | 1.4 Billion USD | 50.572% |
| Boston Scientific Corporation | 9.49 Billion USD | 92.679% |
| Perspective Therapeutics, Inc. | - USD | -Infinity% |
| CONMED Corporation | 991.25 Million USD | 29.897% |
| Paragon 28, Inc. | 112.03 Million USD | -520.28% |
| Glaukos Corporation | 383.73 Million USD | -81.087% |
| Globus Medical, Inc. | 520.4 Million USD | -33.531% |
| Inspire Medical Systems, Inc. | 24.84 Million USD | -2696.828% |
| Integer Holdings Corporation | 1.04 Billion USD | 33.244% |
| Medtronic plc | 26.04 Billion USD | 97.332% |
| Nevro Corp. | 221.82 Million USD | -213.262% |
| Owlet, Inc. | 15.21 Million USD | -4466.903% |
| Penumbra, Inc. | 234.34 Million USD | -196.531% |
| Vicarious Surgical Inc. | 14.83 Million USD | -4585.14% |
| Smith & Nephew plc | 3.08 Billion USD | 77.468% |
| Sonendo, Inc. | 40.35 Million USD | -1622.138% |
| STERIS plc | 3.38 Billion USD | 79.46% |
| Stryker Corporation | 12.99 Billion USD | 94.653% |
| Vapotherm, Inc. | 112.39 Million USD | -518.282% |
| Zimmer Biomet Holdings, Inc. | 5.99 Billion USD | 88.409% |